tirzepatide glp 1 agonist GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Bridging the gap between GLP1-receptor

Rather than diagnosing obesity by BMI alone, it asks whether the excess body fat is actually harming your health

Descriptive analysis Patient demographics (age, sex, and reporter type) and clinical aspects (latency, outcome, and indication) were documented in reports of SSIBs with semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, and albiglutide

Diabetes indications and obesity indications are often treated differently by insurance plans

What the drug does to your risk-profile Subcutaneous semaglutide is the only drug in the analysis with high-certainty evidence of reducing the risk of all-cause death (by roughly 19%) and myocardial infarction (by 28%)

Due to its focus on innovation and modern healthcare provisioning, Germany's healthcare market is quick to adopt novel therapies and has an efficient reimbursement system in place

Individuals receiving the medications through self-pay or other non-plan distribution channels were not included in this analysis